Pediatr Allergy Immunol
Charité-Virchow Klinikum, Kinderklinik und Poliklinik, Berlin, Germany.
Published: September 2005
Atopic eczema begins primarily in infancy or early childhood, and sleep loss due to night-time pruritus can have a considerable impact on patients' and parents' quality of life (QoL). In this study, infants (n = 196) with mild to severe atopic eczema were randomized 2:1, double-blind, to receive either pimecrolimus cream 1% (Elidel, Novartis Pharma, Nürnberg, Germany) or the corresponding vehicle bid for 4 wk, followed by a 12 wk, open-label phase and a 4 wk, treatment-free, follow-up period. The parents' QoL was measured at baseline and at the end of the double-blind phase, using the questionnaire 'QoL in Parents of Children with Atopic Dermatitis' (PQoL-AD), thus data presented here refer to the initial 4-wk treatment phase only. After 4 wk of double-blind treatment, an increase in the mean percentage change from baseline in eczema area and severity index of 71.5% was observed with pimecrolimus, compared with 19.4% with vehicle. The increase in efficacy was paralleled by the following mean percentage changes from baseline in the five domains of the questionnaire in pimecrolimus and vehicle, respectively: psychosomatic well-being: 14.6% vs. 6.2%; effects on social life: 6.7% vs. 2.3%; confidence in medical treatment: 10.0% vs. 3.7%; emotional coping: 16.1% vs. 6.5%; acceptance of disease: 19.6% vs. 7.0%. Analysis (ancova) of the dependent variable difference from baseline and the covariate baseline value revealed values of p < 0.05 for all five domains, despite the very short duration of the study. It is concluded that improvements in atopic eczema in infants achieved by treatment with pimecrolimus have a significant beneficial effect on the QoL of parents.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1399-3038.2005.00306.x | DOI Listing |
Am J Transl Res
December 2024
Department of Respiratory Medicine, Hanzhong People's Hospital Hanzhong 723000, Shaanxi, China.
Objective: To investigate the diagnostic value of immunoglobulin E (IgE), fractional of exhaled nitric oxide (FeNO), and peripheral blood eosinophils (EOS) in adult bronchial asthma and to analyze their relationship with asthma severity.
Methods: A retrospective analysis was conducted on 336 patients diagnosed with bronchial asthma and admitted to Xi'an Fourth Hospital from January 2022 to January 2024, forming the asthma group. Additionally, another 127 healthy subjects were selected as the non-asthmatic control group.
Dermatol Ther (Heidelb)
January 2025
Hospital Universitari Germans Trias I Pujol, UAB, IGTP, Badalona, Spain.
S D Med
September 2024
Avera Medical Group Infectious Disease Specialists, Sioux Falls, South Dakota.
Eczema herpeticum (EH) is a potentially life-threatening condition, especially in the pediatric population, that occurs among patients with atopic dermatitis (AD). AD is a chronic inflammatory skin disorder with a complex pathophysiology that predisposes patients to EH. Herpes simplex virus (HSV) 1 is implicated in 90 % of EH cases and often initially presents with gingivostomatitis.
View Article and Find Full Text PDFAm J Clin Dermatol
January 2025
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response of AD are traditionally reported through clinical assessments including the Eczema Area and Severity Index or Investigator's Global Assessment. These clinical rating scales are visual assessments used in clinical trials to denotate AD severity.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Dermatology, the Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, China. Electronic address:
Many atopic dermatitis (AD) patients have suboptimal responses to Dupilumab therapy. This study identified key genes linked to this resistance using multi-omics approaches to benefit more patients. We selected a prospective cohort of 54 CE treated with Dupilumab from the GEO database.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.